CONFERENCE COVERAGE
Advances in Inflammatory Bowel Diseases
Annual Meeting
2022 COVERAGE
- Rectovaginal Fistulas in Crohn Disease Lead to Debilitating Outcomes Despite Treatment
- Risankizumab Maintenance Therapy Viable Option in Crohn Disease per FDA Criteria
- Behavioral Health Interventions Associated With Improved IBD Symptoms
- IBDQ-32 Accurately Detects Treatment Response in Ulcerative Colitis
- Renal Transplant Improves Outcomes in Half of Patients With Crohn Disease
- Patients Receiving Mirikizumab Report Improved Ulcerative Colitis Symptoms
- Ulcerative Colitis Associated With Risk for Melanoma Skin Cancer
- Pediatric IBD Associated With Antibiotic Exposure Before Age 2 Years
- Smoking Cessation Counseling Infrequent for Crohn Disease in Outpatient Setting
- Transanal and Transabdominal IPAA Have Similar Postsurgical Outcomes in UC
- Ozanimod Efficacious in Patients With Ulcerative Colitis Exposed to Vedolizumab
- Health Disadvantage Contributes to Crohn Disease Symptom Continuation During Remission
Latest Tweets
Follow
@GastroAdv
Conference Coverage from
